Vertical Longevity Pharmaceuticals Raises $110K Seed for VLP Senolytic Vaccines

Vertical Longevity Pharmaceuticals Closes $110K Seed Round

Vertical Longevity Pharmaceuticals, an Irvine, California-based biotechnology company, has raised $110,000 in seed funding. The round was reported on September 28, 2026, with Anthony Young listed among the investors. No lead investor was disclosed.

Company Background

Vertical Longevity Pharmaceuticals was founded in 2024 by CEO David Scieszka. The company develops virus-like particle (VLP) senolytic vaccines. These vaccines are designed to train the immune system to clear senescent cells — a hallmark of aging and a driver of chronic disease.

The scientific premise behind the company's approach is that senescent cells accumulate with age and contribute to a range of age-related conditions. A vaccine that prompts the immune system to target and clear those cells could, in principle, address multiple diseases of aging through a single platform.

Lead Program: Atherosclerosis

The company's lead program targets atherosclerosis, which it describes as the leading cause of death worldwide. In preclinical mouse data, the program has shown plaque prevention and restored cardiac function. Vertical Longevity Pharmaceuticals also has a PCT patent application covering the platform.

Atherosclerosis is a large and well-established indication, and a vaccine-based approach would represent a differentiated mechanism relative to standard lipid-lowering therapies if it translates beyond preclinical models. The company's stated preclinical results — plaque prevention and restored cardiac function in mice — are the kind of early signals that typically attract seed-stage interest in the longevity and immunology spaces.

Research Pipeline and Next Steps

The company is preparing non-human primate efficacy studies with academic collaborators, including Wake Forest University. Non-human primate studies are a meaningful step between rodent models and human trials, and they are often used to de-risk immunogenicity and efficacy before committing to clinical-stage development.

Funding Details

• Company: Vertical Longevity Pharmaceuticals
• Round type: Seed
• Amount: $110,000 USD
• Funding date: September 28, 2026
• Lead investor: Not disclosed
• Investors: Anthony Young
• Headquarters: Irvine, California
• Founded: 2024
• Founder and CEO: David Scieszka
• Stage: Seed

The company is funded through a NetCapital community offering and an accredited-investor tranche. That structure — a regulated community offering alongside a traditional accredited tranche — is increasingly common for early-stage biotech companies seeking to broaden their investor base while still accommodating larger checks from accredited participants.

Platform Potential and Strategic Interest

VLP-based vaccines are an established modality in immunology, which gives the platform a known manufacturing and regulatory framework to build on. Vertical Longevity Pharmaceuticals is applying that modality to senescent cell clearance, a target that sits at the intersection of immunology, aging biology, and cardiology.

If the platform works as intended, the same underlying approach could be directed at multiple senescence-driven conditions beyond atherosclerosis. That kind of platform optionality is typically what strategic acquirers and larger biopharma partners look for in early-stage longevity companies: a lead asset with a clear indication, plus a mechanism that can be extended across a broader pipeline.

Acquisition Angle

For acquirers in longevity, cardiovascular, or vaccine development, Vertical Longevity Pharmaceuticals offers an early-stage but differentiated asset. The combination of a PCT patent application, preclinical mouse data in a major indication, and planned non-human primate studies with academic collaborators gives the company a defined development path.

The $110,000 seed raise is small by biotech standards, which suggests the company is still in a capital-efficient, milestone-driven phase. The NetCapital community offering and accredited-investor tranche indicate a diversified early investor base rather than a single institutional backer.

No valuation, terms, or use-of-proceeds details were disclosed in the funding report.